The Claim
In adults with type 2 diabetes mellitus, a red blood cell lifespan shorter than 66 days is associated with an underestimation of true glycemic control when assessed by HbA1c, resulting in a hemoglobin glycation index (HGI) that indicates a clinically significant discrepancy between measured HbA1c and glucose-predicted HbA1c; this underestimation becomes more pronounced as red blood cell lifespan decreases, potentially leading to missed detection of chronic hyperglycemia.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
If someone with type 2 diabetes has red blood cells that don't live as long as usual, their A1c test might show better blood sugar control than they actually have — meaning doctors could miss signs of high blood sugar over time.
See the scientific wording
In adults with type 2 diabetes mellitus, shorter red blood cell (RBC) lifespan—particularly below 66 days—is associated with underestimation of true glycemic control as measured by HbA1c, leading to a hemoglobin glycation index (HGI) that reflects a clinically significant discrepancy between measured HbA1c and glucose-estimated HbA1c. This underestimation increases with progressively shorter RBC lifespan and may result in inadequate detection of chronic hyperglycemia.
What the research says
1 studyThe study shows that when red blood cells don’t live as long, HbA1c readings can be too low, hiding how high blood sugar really is—especially if cells live less than 66 days. This matches the claim.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.